Search results
Results From The WOW.Com Content Network
Pivotal Phase III trials assess whether a candidate drug has efficacy specifically against a disease, and – in the case of people hospitalized with severe COVID-19 infections – test for an effective dose level of the repurposed or new drug candidate to improve the illness (primarily pneumonia) from COVID-19 infection.
Part of a series on the COVID-19 pandemic Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November ...
The principal for obstetric management of COVID-19 include rapid detection, isolation, and testing, profound preventive measures, regular monitoring of fetus as well as of uterine contractions, peculiar case-to-case delivery planning based on severity of symptoms, and appropriate post-natal measures for preventing infection.
Finding a vaccine for coronavirus has become a public health priority, and researchers across the country are hard at work on different contenders. Here are 3 drugs in development to fight ...
The trial intends to rapidly assess thousands of COVID-19 infected people for the potential efficacy of existing antiviral and anti-inflammatory agents not yet evaluated specifically for COVID-19 illness, a process called "repurposing" or "repositioning" an already-approved drug for a different disease.
The authors came to the conclusion that no further trials of hydroxychloroquine or chloroquine for treatment of COVID-19 should be carried out. [58] On 26 April 2021, in its amended clinical management protocol for COVID-19, the Indian Ministry of Health lists hydroxychloroquine for use in patients during the early course of the disease. [23]
Researchers at Boston’s Dana-Farber Cancer Institute are working on a drug that takes one of the virus’s most dangerous traits — its talent for mutation — and turns it back on itself.
The DAA drugs against hepatitis C are taken orally, as tablets, for 8 to 12 weeks. [56] The treatment depends on the type or types of hepatitis C virus that are causing the infection. [57] Both during and at the end of treatment, blood tests are used to monitor the effectiveness of the treatment and subsequent cure. [56]